These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24051302)

  • 1. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
    José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
    Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
    Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
    Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of residual procoagulants in human intravenous immunoglobulins from 11 Chinese blood fractionation companies.
    Ma L; Sun P; Lin F; Diao G; Li C
    Thromb Res; 2013 Sep; 132(3):381-5. PubMed ID: 23953595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
    Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
    Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
    Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
    Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
    Ma L; Sun P; Lin FZ; Diao G; Li CQ
    Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
    Wolberg AS; Kon RH; Monroe DM; Hoffman M
    Am J Hematol; 2000 Sep; 65(1):30-4. PubMed ID: 10936860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products.
    Germishuizen WA; Gyure DC; Stubbings D; Burnouf T
    Biologicals; 2014 Sep; 42(5):260-70. PubMed ID: 25096922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.
    Seifner A; Beck G; Bayer P; Eichmeir S; Lackner F; Rögelsperger O; Weber K; Wollein G
    Transfusion; 2014 Feb; 54(2):376-83. PubMed ID: 23772713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
    Kang GB; Huber A; Lee J; Kim MJ; Bang E; Hong J; Park S
    Front Cardiovasc Med; 2023; 10():1253177. PubMed ID: 38075963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
    Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
    Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
    Ballow M
    Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG.
    Wu YW; Champagne J; Toueille M; Gantier R; Burnouf T
    Transfusion; 2014 Jan; 54(1):169-78. PubMed ID: 23701287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
    Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
    J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.
    Jorquera JI
    Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):17-21. PubMed ID: 19630865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity.
    Vargas M; Segura Á; Wu YW; Herrera M; Chou ML; Villalta M; León G; Burnouf T
    Vox Sang; 2015 Feb; 108(2):169-77. PubMed ID: 25469648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.
    Diez JM; Caballero S; Belda F; Otegui M; Gajardo R; Jorquera JI
    Biologicals; 2010 Nov; 38(6):670-4. PubMed ID: 20863716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
    Behr-Gross ME; Le Tallec D; Sinitskaya N; Milne C; Etscheid M
    Pharmeur Bio Sci Notes; 2024; 2024():27-75. PubMed ID: 38533680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
    Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.